Skip to main content
MJH Life Sciences
  • Login
  • Register
  • Login
  • Register
Home
  • Topics
  • News
  • Blogs
  • Image IQ
  • Podcasts
  • Conferences
MJH Life Sciences

SUBSCRIBE: eNewsletter

Anna Azvolinsky

FDA Approves New Drug for Bladder Cancer

May 19, 2016
  • Anna Azvolinsky

The FDA has granted accelerated approval to atezolizumab (Tecentriq) for the treatment of locally advanced or metastatic urothelial carcinoma—the most common type of bladder cancer.

  • READ >>

CD4 T-Cell Immunotherapy Active in Various Cancers

April 19, 2016
  • Anna Azvolinsky

Results of a trial involving a CD4-based immunotherapy has shown activity in patients with metastatic solid tumors, according to phase I data presented at the AACR Annual Meeting.

  • READ >>

PTEN Mutation Status Potential Biomarker for Endometrial Cancer Therapies

March 25, 2016
  • Anna Azvolinsky

Loss of function of the PTEN tumor suppressor gene leads to resistance to therapies targeting the Notch signaling pathway according to a mouse study presented at the 2016 Society of Gynecologic Oncology annual meeting, held in San Diego, March 19-22, 2016.

  • READ >>

DNA Methylation Signature Found in Common to Several Tumor Types

February 17, 2016
  • Anna Azvolinsky

Detection of an epigenetic signature found in five different common tumor types—colon, lung, breast, stomach, and endometrial cancers—may be useful in diagnosing early-stage tumors using a blood test.

  • READ >>

ASCO Issues Guideline on Biomarker-Based Adjuvant Breast Cancer Treatment

February 9, 2016
  • Anna Azvolinsky

ASCO has published a guideline on biomarker use to guide decisions for adjuvant systemic treatment for women with early-stage, invasive breast cancer.

  • READ >>

Pan-Mutation Test for Brain Tumors

February 9, 2016
  • Anna Azvolinsky

Researchers at the University of Pittsburgh have developed a sequencing test to analyze a broad spectrum of genetic alterations in central nervous system (CNS) tumors.

  • READ >>

Early-Stage Clinical Trials Underestimate Small Molecule, Targeted Anticancer Drug Toxicity

January 19, 2016
  • Anna Azvolinsky

Dose-determining phase I clinical trials may not correctly determine the appropriate doses of small molecule oncology drugs to administer in larger, later stage trials.

  • READ >>

Circulating Tumor DNA Analysis for Liquid Biopsies in Breast Cancer

December 18, 2015
  • Anna Azvolinsky

We are speaking with Maximilian Diehn, MD, PhD, on developing genomics-based biomarkers to identify the presence of cancer cells for prognosis and predicting response to cancer therapies.

  • READ >>

FDA Grants Crizotinib Priority Review in ROS1-Mutated Lung Cancer

December 16, 2015
  • Anna Azvolinsky

The targeted, oral therapy crizotinib (Xalkori), has been granted priority review by the US Food and Drug Administration (FDA) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) who have c-ros oncogene 1 (ROS1)-rearranged tumors.

  • READ >>

FDA Approves Alectinib for ALK-Positive NSCLC

December 14, 2015
  • Anna Azvolinsky

On December 11, 2015, the US Food and Drug Administration (FDA) approved alectinib for patients with ALK-rearrangement positive non-small cell lung cancer (NSCLC) that is refractory to another ALK-targeted oral drug, crizotinib.

  • READ >>

Pages

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • next ›
  • last »
Connect with Us
  • Column 1
    • Home
    • About Us
    • Contact Us
  • Column 2
    • Editorial Info
    • Editorial Board
  • Column 3
    • Advertising Info
    • Reprints
    • Advertising Terms
  • Column 4
    • Terms of Use
    • Privacy Policy
Modern Medicine Network
© UBM 2019, All rights reserved.
Reproduction in whole or in part is prohibited.

We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".